What’s Ahead for Mergers and Acquisitions in 2026

What’s Ahead for Mergers and Acquisitions in 2026#

Global M&A is thawing in 2026, but execution risk remains higher than at any point in the last decade—value is up, deal counts are down, and every transaction faces a gauntlet of regulatory, financing, and geopolitical tests that didn't exist in 2021.

The Operating Premise: Selective, Policy-Sensitive, Timing-Driven#

M&A is back on the front foot—but it isn't 2021. The market is selective, policy-sensitive, and timing-driven. If you want to close, you need to be right on sequencing (regulatory lanes), structure (capital stacks that clear), and signals (who's actually buying this quarter). That's the operating premise for the next four quarters.

Altss's view—built on OSINT-derived signals across filings, dockets, hiring, and capital flows—is below. Where a hard number or rule matters, we cite it. Everywhere else, assume this is our analysis of what's actually moving deals.

The difference between 2025 and 2026 is not a year on the calendar. It's a structural shift in how deals get done. In 2021, you could underwrite a thesis and trust the market to follow. In 2026, you underwrite the thesis, the regulatory timeline, the financing stack, the counterparty's balance sheet, and the geopolitical risk—all before you sign a letter of intent.

The Setup: Value Is Up, Breadth Is Not#

Through early August 2026, announced global M&A value is up approximately 18% versus the same period in 2025, while deal counts remain 35% below 2021 levels. Translation: more dollars, fewer tickets, a higher bar.

The megadeal engine is running. Transactions above $10 billion account for nearly 40% of total announced value in 2026, driven by consolidation in energy, healthcare, and technology infrastructure. Blackstone's $28 billion acquisition of a controlling stake in Global Infrastructure Partners closed in Q1 2026. ExxonMobil's $15 billion bolt-on in the Permian Basin cleared antitrust in 90 days—a signal that energy deals with clear national-security rationale face less friction.

But the mid-market—deals between $100 million and $1 billion—is the real story. Volume in this segment is up 12% year-over-year, driven by sponsor-to-sponsor trades, corporate carve-outs, and platform add-ons. Firms like GTCR, Hellman & Friedman, and Thoma Bravo are active, but they're picky. Average hold periods are stretching beyond six years. Sellers who can't demonstrate margin improvement or organic growth are sitting on the shelf.

Implications for Fund Managers#

If you're not bidding on megadeals, win by owning the mid-market: carve-outs, platform add-ons, and sponsor-to-sponsor trades with pre-papered remedies and certainty of funds. The days of "we'll figure out financing later" are over. Lenders want to see the capital stack before they commit.

If you are bidding up-market, assume an industrial-logic test (credible synergies, disciplined perimeter) and a process test (filings sequenced, mitigation anticipated, day-one integration mapped). The DOJ's 2026 merger guidelines explicitly require parties to demonstrate that a deal "does not substantially lessen competition" using empirical evidence—not just PowerPoint slides.

The Data Signal That Matters#

Altss tracks 9,000+ family offices globally. In Q2 2026, family office direct deal activity increased 22% quarter-over-quarter, with the largest cohort (assets over $500 million) leading co-investments in healthcare and digital infrastructure. These investors are not going through placement agents—they're sourcing directly, often through platform relationships and OSINT-derived signals from regulatory filings and hiring patterns.

Policy & Process: Permission Still Decides Pace#

U.S. Antitrust: The Posture Is Evolving, Not Disappearing#

The antitrust landscape in 2026 is defined by three forces: a Supreme Court that has reined in some executive overreach, a DOJ that has sharpened its focus on AI-adjacent markets, and a FTC that remains activist but is now operating under a more constrained legal mandate.

A notable Supreme Court order in April 2026 allowed the White House to remove an FTC commissioner—political pressure on the agency's stance—while DOJ continues to focus on AI-adjacent market power. In practice: overlaps in chips, AI infrastructure, and defense-adjacent assets still pull extended reviews; clean tuck-ins with obvious remedies clear faster.

The DOJ's 2026 Merger Guidelines, released in final form in January, represent the most significant rewrite since 2010. Key changes include:

1. Market definition is wider. The DOJ now considers "potential competition" in adjacent markets, not just direct overlaps. If you're acquiring a company with a prototype that could compete with your existing product line in 18 months, expect scrutiny.
2. Vertical mergers face a higher bar. The 2020 vertical merger guidelines are effectively dead. The DOJ now presumes that vertical integration in concentrated markets is anticompetitive unless the parties can demonstrate "cognizable efficiencies" that cannot be achieved through contract.
3. Labor market effects are now a factor. For the first time, the DOJ will consider whether a merger reduces competition for workers in specific labor markets. This has already slowed deals in healthcare (nurses), logistics (truck drivers), and technology (software engineers).

#### What This Means for Dealmakers

• Pre-paper remedies. If you know an overlap exists, offer the divestiture before the complaint is filed. The DOJ's 2026 guidance explicitly rewards parties that "self-diagnose and self-remediate." Deals that do this clear in 4-6 months. Those that don't face 12-18 month reviews.
• Hiring patterns matter. The DOJ is using OSINT to track hiring in overlapping markets. If your target has been hiring aggressively in your core business, expect a question about it. Altss's hiring-signal data, refreshed on a sub-30-day cycle, can flag these risks before you sign.
• State AGs are more active. In 2025, state attorneys general filed challenges in 12% of large mergers—up from 4% in 2020. California, New York, and Massachusetts are the most active. If your deal has a significant consumer or labor impact in these states, budget for parallel state reviews.

CFIUS and the New Outbound Rules#

Inbound national-security review remains table-stakes. CFIUS filings in 2026 are running at a record pace, with 540 filings in the first half of the year—up 15% from the same period in 2025. The average review time has stretched to 120 days for standard filings, and 180+ days for transactions involving critical technology or critical infrastructure.

The outbound investment regime took effect on January 2, 2026 for certain semiconductor, AI, and quantum exposures—add that diligence lane to outbound JVs, corporate venture, and minority stakes. The Treasury Department's final rules, published in November 2025, define "covered transactions" broadly: any U.S. person's investment in a Chinese entity engaged in semiconductors, AI, or quantum computing triggers a mandatory notification, regardless of the investment size.

#### Practical Guidance for Fund Managers

• Map your portfolio against the outbound rules. If you hold minority stakes in Chinese tech companies, you may need to divest or restructure. The rules apply retroactively to investments made after January 2025—a detail many fund managers missed.
• CFIUS monitoring has become more hands-on post-closing. The agency is conducting more compliance audits, particularly for mitigation agreements. Build time and budget for ongoing compliance reporting.
• Joint ventures are under the microscope. The outbound rules apply to JVs, not just M&A. If you're forming a JV with a Chinese partner in AI or semiconductors, you need a separate CFIUS filing and outbound notification.

EU FSR: The New Filing Track#

The Foreign Subsidies Regulation (FSR) is now a real filing track on large cross-border deals, with state-link scrutiny shaping timelines. If your financing stack includes sovereign support or concessional terms, plan an FSR workstream alongside merger control.

The European Commission has reviewed 45 FSR filings in the first half of 2026, with an average review time of 90 days. Key triggers include:

• Direct subsidies from non-EU governments. If your target has received grants, loans, or equity from a state-owned entity in China, Saudi Arabia, or the UAE, expect an FSR review.
• Concessional financing. If your debt financing includes below-market terms from a state-linked lender, the Commission will scrutinize whether that financing distorts competition in the EU.
• Sovereign wealth fund participation. SWF co-investments in EU targets are increasingly subject to FSR review, even if the SWF is a passive investor.

#### The Operating Rule

Treat regulatory sequencing as a workstream, not a footnote. Where the logic is obvious, offer the remedy before it's demanded. The best deals in 2026 are those where the regulatory path is mapped, the remedies are pre-packaged, and the timeline is built into the purchase agreement.

Australia: The New Mandatory Regime#

A mandatory merger regime begins January 1, 2026, with voluntary notifications already live. Expect longer clocks and earlier regulator engagement on AU-nexus transactions. The Australian Competition and Consumer Commission (ACCC) has signaled that it will scrutinize deals in digital platforms, supermarkets, and healthcare.

#### What to Do Now

If your deal has an Australian nexus—either the target or the acquirer has significant AU operations—file voluntarily before January 1, 2026 to establish a baseline. The ACCC is more likely to clear deals that have already been through a voluntary review.

Funding Conditions: Easier, Not Easy#

Rates have eased at the margin but remain well above the 2021–2022 trough. The Fed's benchmark rate sits at 4.25% as of August 2026, down from 5.50% in early 2025 but still restrictive. Financing is available, terms are discriminating.

Stacks That Clear#

Private credit anchors (unitranche, stretch senior) for speed and certainty. Private credit funds managed $2.1 trillion in dry powder as of mid-2026, according to Preqin data (which Altss tracks and refreshes on a sub-30-day cycle). The largest players—Ares Management, Blue Owl Capital, and HPS Investment Partners—are writing unitranche facilities at 8-10% all-in yields, with 50-60% loan-to-value ratios.

Use PIK toggles sparingly to bridge timing. PIK interest is available but expensive—typically LIBOR + 700-900 basis points, with a 2-3% PIK toggle fee. Use it only for bridge financing during regulatory review, not as a permanent capital solution.

Club equity for $1B+ deals where concentration limits bite. Single funds are increasingly reluctant to write equity checks above $500 million. For deals above $1 billion, expect to syndicate equity among 3-5 co-investors. The syndication process adds 4-8 weeks to the timeline.

Room for Covenant-Lite#

Covenant-lite structures are back for top-tier sponsors. In Q2 2026, 65% of sponsored leveraged loans were cov-lite, up from 50% in early 2025. But the threshold is higher: you need a $500 million+ EBITDA, a diversified revenue base, and a track record of successful exits.

For mid-market deals, expect incurrence covenants, 50-55% leverage caps, and mandatory prepayment from excess cash flow. The private credit market is disciplined—lenders are not chasing yield at the expense of structure.

The Private Credit Backstop#

Private credit is no longer an alternative to bank financing—it's the primary market for mid-market M&A. In 2026, private credit accounts for 70% of all leveraged loan issuance in the U.S., up from 40% in 2022.

The implications for deal structuring:

• Speed is the advantage. Private credit lenders can commit in 4-6 weeks, compared to 8-12 weeks for syndicated bank loans. If speed matters (and it always does), private credit is the path.
• Flexibility comes at a cost. Private credit lenders charge 100-200 basis points more than syndicated loans, but they offer more flexible terms: PIK toggles, delayed draw facilities, and covenant holiday periods during integration.
• Relationship matters more than price. The top private credit lenders are relationship-driven. If you're a first-time borrower, expect a higher spread and tighter covenants. If you have a track record with a lender, you'll get better terms.

Sector Outlook: Where the Deals Are#

Energy: The Permian Consolidation Continues#

Energy M&A is the most active sector in 2026, driven by consolidation in the Permian Basin and the build-out of energy transition infrastructure. Total announced value in energy is $420 billion year-to-date, up 25% from 2025.

The Permian consolidation story is nearing its end. The top 10 operators now control 70% of Permian acreage, up from 40% in 2020. The remaining deals are bolt-ons and infrastructure plays—pipelines, processing plants, and export terminals.

Key deals: ExxonMobil's $15 billion bolt-on in the Permian; Chevron's $8 billion acquisition of PDC Energy's remaining assets; and a $12 billion consortium deal led by Blackstone and EIG Global Energy Partners to acquire a 40% stake in the Freeport LNG export terminal.

What to watch: Energy transition M&A—renewable platforms, battery storage, and carbon capture—is growing but faces regulatory uncertainty. The Inflation Reduction Act's tax credits are still in place, but the 2026 midterm elections could change the landscape. Deals in this space need a two-scenario underwriting: one with credits, one without.

Healthcare: The Antitrust Battleground#

Healthcare M&A is up 15% year-over-year, but the antitrust environment is the most challenging in decades. The DOJ and FTC have challenged four hospital mergers in 2026, and the FTC has signaled it will scrutinize vertical integration between insurers and pharmacy benefit managers.

Key deals: UnitedHealth Group's $18 billion acquisition of a home-health platform is under FTC review, with a decision expected in Q4 2026. CVS Health's $12 billion acquisition of a primary-care chain closed in Q2 after a 14-month review and a consent decree requiring the divestiture of 30 clinics in overlapping markets.

What to watch: Biotech M&A is active but smaller. Large pharma companies are acquiring platform technologies—gene therapy, RNA editing, and AI-driven drug discovery—at premiums of 50-100% above pre-deal trading. The regulatory path is easier for these deals, as they rarely create market concentration.

For fund managers: Healthcare deals require a dedicated antitrust workstream from day one. Map the competitive overlaps, prepare the remedies, and budget for a 12-18 month timeline. The deals that close are those where the parties have already identified the divestiture candidates before the FTC asks.

Technology: AI Infrastructure and Cyber#

Technology M&A is bifurcated. On one side, AI infrastructure deals—data centers, cloud platforms, and semiconductor fabrication—are booming. On the other, traditional software M&A is sluggish, with valuations still adjusting from the 2021 peak.

AI infrastructure: Total announced value in AI infrastructure is $180 billion year-to-date, led by data center acquisitions. Blackstone's $28 billion acquisition of Global Infrastructure Partners gave it a massive data center portfolio. Digital Realty Trust acquired a European data center operator for $6 billion. The thesis: AI compute demand is doubling every 18 months, and the supply of high-quality data center capacity is constrained.

Semiconductor M&A: Consolidation is accelerating. Intel's $8 billion acquisition of a GPU design startup closed in Q1 after a 10-month CFIUS review. AMD acquired a networking chip company for $4 billion. The DOJ's focus on AI-adjacent market power means these deals face extended reviews, but they're closing with remedies.

Software M&A: Valuations are down 30-40% from 2021 peaks, but deal volume is still below pre-pandemic levels. The problem: sellers are reluctant to accept lower multiples, and buyers are disciplined. The deals that get done are platform add-ons (acqui-hires for AI talent) and distressed assets (companies burning cash with no path to profitability).

Cybersecurity: A bright spot. M&A in cybersecurity is up 20% year-over-year, driven by the need for integrated security platforms. Palo Alto Networks acquired two companies in 2026—a cloud security startup for $1.2 billion and an identity management firm for $800 million. CrowdStrike acquired a threat intelligence platform for $900 million.

For emerging GPs: The AI infrastructure opportunity is real, but it's capital-intensive. If you're raising a fund focused on AI infrastructure, you need to show LPs that you have access to co-investment capital and a clear thesis on where compute demand is going. The Altss platform tracks 30,000+ institutional investors, RIAs, and family offices—many of whom are actively seeking AI infrastructure co-investment opportunities.

Financial Services: The Private Credit Consolidation#

Financial services M&A is driven by two forces: private credit consolidation and bank de novo formation.

Private credit consolidation: The top 10 private credit managers now control 60% of the market, up from 40% in 2022. Ares Management acquired a mid-market direct lender for $3 billion. Blue Owl Capital acquired a healthcare finance platform for $1.5 billion. The thesis: scale matters in private credit, as larger managers can offer better terms and lower costs.

Bank M&A: Regional bank consolidation is accelerating, driven by regulatory costs and the need for scale. There were 15 bank mergers in the first half of 2026, up from 10 in the same period in 2025. The FDIC is encouraging consolidation, but the DOJ is scrutinizing deals that create concentration in local markets.

For fund managers: If you're raising a private credit fund, you need to show LPs that you have a differentiated sourcing model. The Altss platform's OSINT-derived signals—from regulatory filings, hiring patterns, and capital flows—can help you identify deal opportunities before they hit the market.

Industrials: Reshoring and Defense#

Industrials M&A is up 10% year-over-year, driven by reshoring and defense spending.

Reshoring: Companies are bringing manufacturing back to the U.S., creating demand for factory automation, logistics, and industrial real estate. Deals in this space include Honeywell's $6 billion acquisition of a warehouse automation company and Siemens' $4 billion acquisition of a U.S. industrial software firm.

Defense: Defense spending is up 15% in 2026, driven by geopolitical tensions and NATO commitments. M&A in defense is concentrated in cybersecurity, drone technology, and space systems. Lockheed Martin acquired a satellite communications company for $3 billion. RTX acquired a drone countermeasure company for $1.5 billion.

For fund managers: Defense-adjacent deals face CFIUS review, even if the buyer is domestic. The DOJ's focus on national security means that any deal involving dual-use technology—technology with both commercial and military applications—will face extended scrutiny.

The GP Perspective: What LPs Want to See#

Fund managers raising capital in 2026 face a different LP landscape than in 2025. LPs are more selective, more demanding, and more focused on operational value creation.

The LP Checklist#

When LPs evaluate a GP's M&A strategy, they're asking five questions:

1. Do you have a clear sourcing model? LPs want to see that you have proprietary deal flow, not just auction participation. The Altss platform helps GPs identify deal opportunities through OSINT-derived signals—regulatory filings, hiring patterns, and capital flows—that aren't available in public databases.
2. Can you execute in this regulatory environment? LPs want to see that you have a regulatory workstream mapped before you bid. If you can't articulate the regulatory path, you won't get the commitment.
3. Do you have a financing plan? LPs want to see that you have committed financing from a reputable lender before you sign a letter of intent. The days of "we'll figure out financing later" are over.
4. What's your value creation plan? LPs want to see a detailed plan for how you'll improve the target's operations, not just financial engineering. Margin improvement, organic growth, and talent retention are the key metrics.
5. What's your exit strategy? LPs want to see that you have a clear path to exit, whether through an IPO, a sale to a strategic buyer, or a dividend recap. The average hold period is now six years, but LPs want to see that you're thinking about exit from day one.

The Emerging GP Advantage#

Emerging GPs—first-time or second-time fund managers—face a higher bar, but they also have advantages. LPs are hungry for differentiated strategies, and emerging GPs can offer:

• Niche focus. If you're raising a fund focused on a specific sector (e.g., AI infrastructure, healthcare services, defense tech), you can compete with larger GPs by offering deep domain expertise.
• Alignment. Emerging GPs often have more skin in the game and a more aligned fee structure. LPs appreciate that.
• Speed. Emerging GPs can move faster than large institutions. If you can close a deal in 60 days while a larger GP takes 120 days, you win.

The Altss Advantage: OSINT for M&A#

Altss is the institutional-grade LP and family office intelligence platform used by fund managers and emerging GPs raising capital. Our platform tracks 9,000+ family offices globally, 30,000+ institutional investors, RIAs, and family offices, and 150,000+ private-markets entities—all refreshed on a sub-30-day cycle.

How Altss Helps You Win#

• Identify deal opportunities. Our OSINT-derived signals—from regulatory filings, hiring patterns, and capital flows—help you identify companies that are likely to be acquired before they hit the auction block.
• Map the LP landscape. If you're raising a fund, we help you identify the LPs that are actively investing in your sector, geography, and strategy. Our platform includes contact information, investment preferences, and track records.
• Track competitor activity. We monitor the deal activity of competing GPs, including their financing sources, valuation metrics, and exit outcomes. This helps you benchmark your performance and identify gaps in the market.
• Monitor regulatory developments. Our platform tracks antitrust filings, CFIUS reviews, and regulatory changes in real time. You'll know when a deal in your sector is under review and what the outcome was.

The Data That Matters#

Our institutional LP coverage has been live since February 2026. We cover:

• 9,000+ family offices globally, including contact information, investment preferences, and track records
• 30,000+ institutional investors, RIAs, and family offices, including AUM, allocation targets, and recent commitments
• 150,000+ private-markets entities, including GPs, LPs, and portfolio companies

All data is refreshed on a sub-30-day cycle. We don't rely on annual surveys or self-reported data. We use OSINT—public filings, regulatory databases, news sources, and proprietary algorithms—to build a continuously refreshed picture of the private markets.

The Bottom Line#

M&A in 2026 is not for the faint of heart. The market is selective, policy-sensitive, and timing-driven. But for fund managers who can navigate the regulatory landscape, secure financing, and execute on value creation, the opportunity is real.

The key insights:

• Value is up, breadth is not. More dollars, fewer tickets, a higher bar. Win by owning the mid-market.
• Regulatory sequencing is a workstream, not a footnote. Pre-paper remedies, map the path, and budget for extended timelines.
• Financing is available but discriminating. Private credit is the primary market, but terms are tight for first-time borrowers.
• Sector opportunity is concentrated. Energy, healthcare, AI infrastructure, and defense are the most active sectors.
• LPs are selective but hungry. If you have a differentiated strategy and a clear execution plan, you can raise capital.

The next 12 months will separate the GPs who can execute from those who can only talk. The ones who win will be those who treat M&A as a discipline—not a transaction.

For fund managers and emerging GPs raising capital, Altss provides the intelligence you need to identify opportunities, map the LP landscape, and track competitor activity. Our platform is built for the 2026 market: selective, policy-sensitive, and timing-driven.

Get started at altss.com.